Compare JetBlue Airways Corporation (JBLU) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JetBlue Airways Corporation vs Johnson & Johnson — how do they compare? JetBlue Airways Corporation trades at $3.85 (market cap $1.48B), while Johnson & Johnson trades at $261.43 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 417.6× JetBlue Airways Corporation's market cap, and Johnson & Johnson pays a 2.09% dividend while JetBlue Airways Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold JetBlue Airways Corporation for 44 Days and Johnson & Johnson for 129 Days on average.
| JBLU | JNJ | |
|---|---|---|
Market Cap | $1.48B | $618.09B |
Volume | 30,275,693 | 6,050,983 |
Sector | Industrials | Health |
52-Week High | $6.46 | $278.43 |
52-Week Low | $3.92 | $186.00 |
Typical Hold Time | 44 Days | 129 Days |
Enterprise Value | $8.84B | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JetBlue (JBLU) trades at $3.84, down 3.27% today, reflecting ongoing challenges in the airline sector. The stock shows bearish technical signals with negative moving averages and oscillators. Fundamentally, JBLU reported a net loss of $602 million in 2025 with negative profit margins, though revenue remains stable at $9.06 billion. Recent developments include route expansion to Colombia and the launch of BlueFirst premium seating, while activist investor Carl Icahn recently reduced board representation.
The outlook remains challenging with elevated fuel costs and competitive pressures. While the stock trades below book value (P/B 0.93) and analyst consensus target of $5.89, persistent losses and high debt levels pose significant risks. Institutional buying by Bank of America provides some support, but profitability improvement is essential for sustained recovery.
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
